Please assess the completion status of the following clinical trial:

Trial Title: Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with type 2 diabetes mellitus treated with insulin glargine once daily and oral blood glucose lowering medication~* Patients with a HbA1c \> 7%~* Patients with a FBG within range (4-7 mmol/L) at baseline, based on the mean of 3 FBG values (measured 5x during the run-in phase, with the highest and lowest value excluded)~Exclusion criteria:~* Patients treated with an insulin other than insulin glargine~* Patients with hypersensitivity to insulin glargine, insulin glulisine, biphasic insulin aspart/insulin aspart protamine 30/70 or any of the excipients~* Patients with a (pre)proliferative retinopathy (an optic fundus examination should have been performed within the 2 years prior to study entry)~* Pregnant or lactating women~* Patients who are unable to fill in the PRO (Patient Reported Outcomes) questionnaires~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine + Insulin glulisine (Type: EXPERIMENTAL): Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
- Premixed insulin (Type: ACTIVE_COMPARATOR): twice daily premixed insulin (before breakfast and evening meal).

Based on this trial design, predict the completion outcome and termination type (if applicable).